• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis

byRavi Shah, MD MBA
July 28, 2019
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

United States medical cannabis registration increased significantly between 2016 and 2020

Rilzabrutinib demonstrates rapid and durable clinical activity for immune thrombocytopenia

#VisualAbstract Acalabrutinib monotherapy has acceptable tolerability and limited response in patients with Richter transformation

1. The Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib when compared to placebo treatment in multiple sclerosis patients showed the ability to reduce the number of gadolinium enhancing lesions on MRI imaging.

2. Key clinical outcomes of annualized relapse rates or change in a disability score were not different between patients treated with placebo compared to evobrutinib at 24 weeks. 

Evidence Rating Level: 1 (Excellent)  

Study Rundown: Multiple sclerosis (MS) is a progressive, demyelinating autoimmune disease that forms identifiable lesions in the central nervous system. Clinical goals of treatment are to reduce the frequency of relapse events and to slow disease progression. In addition to clinical measures of treatment efficacy, imaging findings of lesions in the central nervous system can be used as a proxy market for treatment efficacy. B cells involved in autoimmune disease are thought to play a role in MS, and thus augmenting their activity through the BTK signaling cascade may reduce their effect on MS disease progression. This phase 2 trial evaluated the BTK inhibitor evobrutinib compared to placebo and showed high doses of evobrutinib can significantly reduce the number of central nervous system lesions identified on MRI in MS patients, though clinical markers of disease progression were not altered with evobrutinib treatment at 24 weeks.

The strengths of this study include its evaluation of a novel therapy in a progressive disease, study of multiple dosing regimens, and use of dimethyl fumarate (DMF) as a reference therapy. The study is limited by the generalizability of the patient population, limited study size segmented into multiple treatment groups, and lack of comparison between the evobrutinib and DMF groups. Longer trials will be need to determine evobrutinib’s long term efficacy.

Click to read the study in NEJM

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Bruton’s tyrosine kinase (BTK) inhibitorevobrutinibmultiple sclerosis
Previous Post

Quick Take: The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT)

Next Post

Differences in NICU quality and access leads to racial disparities in neonatal outcomes

RelatedReports

Parental cannabis use increasing, cigarette use decreasing
Chronic Disease

United States medical cannabis registration increased significantly between 2016 and 2020

June 29, 2022
Long-term dual antiplatelet therapy does not increase mortality risk
Chronic Disease

Rilzabrutinib demonstrates rapid and durable clinical activity for immune thrombocytopenia

April 22, 2022
#VisualAbstract Acalabrutinib monotherapy has acceptable tolerability and limited response in patients with Richter transformation
StudyGraphics

#VisualAbstract Acalabrutinib monotherapy has acceptable tolerability and limited response in patients with Richter transformation

November 11, 2021
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Factors associated with earlier clinical symptom onset in radiologically isolated multiple sclerosis

October 12, 2021
Next Post
Poverty, preterm birth demonstrate additive effect on cognition

Differences in NICU quality and access leads to racial disparities in neonatal outcomes

2 Minute Medicine Rewind July 29, 2019

2 Minute Medicine Rewind July 29, 2019

Quick Take: Short-course primaquine for the radical cure of Plasmodium vivax malaria

Quick Take: Short-course primaquine for the radical cure of Plasmodium vivax malaria

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.